Clinical Trial Update: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study evaluating palbociclib in postmenopausal Chinese women with ER-positive, HER2-negative advanced breast cancer; the study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Pfizer | Conditions: Advanced Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-07-29